C5 ANTIBODY AND METHOD FOR PREVENTING AND TREATING COMPLEMENT-RELATED DISEASES Russian patent published in 2018 - IPC C07K16/18 A61K39/395 

FIELD: biochemistry.

SUBSTANCE: described is an antibody or antigen-binding fragment thereof that specifically bind to the MG4 domain in the beta chain of the protein of complement 5 (C5), wherein the antibody comprises a heavy chain complementarity determining region 1 (CDR1) selected from the group consisting of SEQ ID NOs: 1, 11, 21, 31, 41 and 51, CDR2 a heavy chain selected from the group consisting of SEQ ID NOs: 2, 12, 22, 32, 42 and 52, CDR3 heavy chain SEQ ID NO: 3, CDR1 light chain SEQ ID NO: 4, CDR2 light chain SEQ ID NO: 5 and CDR3 light chain SEQ ID NO: 6. Also described is a monoclonal antibody binding to a human C5 protein, or an antigen-binding fragment thereof, comprising a heavy chain variable region having at least 95% sequence identity with SEQ ID NO: 7, 17, 27, 37, 47 or 57; and a light chain variable region having at least 95% sequence identity with SEQ ID NO: 8. In addition, a monoclonal antibody binding to a human C5 protein or an antigen-binding fragment thereof containing a heavy chain having at least 95% sequence identity with SEQ ID NO: 9, 19, 29, 39, 49 or 59; and a light chain having at least 95% sequence identity with SEQ ID NO: 10. Described is a nucleic acid encoding a monoclonal antibody binding to a human C5 protein, or an antigen-binding fragment thereof comprising a heavy chain variable region having at least 95% sequence identity with SEQ ID NO: 7, 17, 27, 37, 47 or 57; and a light chain variable region having at least 95% sequence identity with SEQ ID NO: 8. Corresponding expression vector and host cell are also described.

EFFECT: pharmaceutical composition is provided for the treatment of diseases caused by component 5 complement comprising any of said antibodies and a suitable method of treatment.

28 cl, 19 dwg, 14 tbl, 11 ex